Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?
Post-transplant lymphoproliferative disorders (PTLDs) are serious, life-threatening complications of solid-organ transplantation (SOT) and bone marrow transplantation leading to a high mortality (30-60%). PTLD represents a heterogeneous group of lymphoproliferative diseases. They become clinically relevant because of the expansion of transplantation medicine together with the development of potent immunosuppressive drugs. Although the diagnostic morphological criteria of different forms of PTLD are commonly known, rapid and correct diagnosis is not always easy. Because of the limited number of clinical trials, a consensus is lacking on the optimal treatment of PTLD. This review focuses on incidence, risk factors, clinical picture of the disease and diagnostic tools including histopathology relating to the new classification introduced in 2008 by the World Health Organisation (WHO) and treatment of PTLD.
Mucha
Krzysztof
K
Transplantation Institute, Department of Immunology, Transplantology and Internal Medicine, Warsaw Medical University, Warsaw, Poland. kjmucha@gmail.com
Foroncewicz
Bartosz
B
Ziarkiewicz-Wróblewska
Bogna
B
Krawczyk
Marek
M
Lerut
Jan
J
Paczek
Leszek
L
D000465:Algorithms; D006801:Humans; D015994:Incidence; D008232:Lymphoproliferative Disorders / Q000145:classification* / Q000453:epidemiology* / Q000628:therapy; D016377:Organ Transplantation / Q000009:adverse effects*; D012307:Risk Factors; D014944:World Health Organization